arznei-telegramm® 03/2016 |
SPOT ON |
Oncological drugs in oversized injection vials … cause waste for millions of euros |
NEW ON THE MARKET |
Ticagrelor (BRILIQUE) for permanent treatment after myocardial infarction? |
Guanfacine (INTUNIV RETARD) as attention deficit hyperactivity disorder drug |
THERAPY FROM A CRITICAL VIEWPOINT |
Baclofen (LIORESAL, generics) for alcohol dependency? |
a-t READER'S QUESTIONS AND COMMENTS |
Vaccination in the case of TNF-alpha inhibitors during pregnancy |
IN BRIEF |
Ezetimibe now also for cardiovascular prevention? |
On the safety of long-acting beta-agonists in asthma |
Prescribability of glinide antidiabetics restricted | Quiet end to the anti-malarial drug mefloquine (LARIAM) |
CURRENT ADR NETWORK REPORT |
Is evolocumab (REPATHA) diabetogenic? |
SIDE EFFECTS |
Fatal infections with idelalisib (ZYDELIG) |
e a-t IN THE INTERNET |
Oncological drugs in oversized injection vials … cause waste for millions of euros |
Flibanserin: libido drug with unsatisfying effect |